197 related articles for article (PubMed ID: 34485908)
21. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
22. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
23. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
24. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
25. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.
Wightman F; Lu HK; Solomon AE; Saleh S; Harman AN; Cunningham AL; Gray L; Churchill M; Cameron PU; Dear AE; Lewin SR
AIDS; 2013 Nov; 27(18):2853-62. PubMed ID: 24189584
[TBL] [Abstract][Full Text] [Related]
26. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.
Martin BP; Frew AJ; Bots M; Fox S; Long F; Takeda K; Yagita H; Atadja P; Smyth MJ; Johnstone RW
Int J Cancer; 2011 Jun; 128(11):2735-47. PubMed ID: 20715169
[TBL] [Abstract][Full Text] [Related]
28. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
Ali SR; Humphreys KJ; McKinnon RA; Michael MZ
Drug Dev Res; 2015 Sep; 76(6):296-317. PubMed ID: 26303212
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
Salahuddin A; Ghanem H; Omran GA; Helmy MW
Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.
Staberg M; Michaelsen SR; Rasmussen RD; Villingshøj M; Poulsen HS; Hamerlik P
Cell Oncol (Dordr); 2017 Feb; 40(1):21-32. PubMed ID: 27766591
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
[TBL] [Abstract][Full Text] [Related]
32. Differential regulation of H3K9/H3K14 acetylation by small molecules drives neuron-fate-induction of glioma cell.
Liu X; Guo C; Leng T; Fan Z; Mai J; Chen J; Xu J; Li Q; Jiang B; Sai K; Yang W; Gu J; Wang J; Sun S; Chen Z; Zhong Y; Liang X; Chen C; Cai J; Lin Y; Liang J; Hu J; Yan G; Zhu W; Yin W
Cell Death Dis; 2023 Feb; 14(2):142. PubMed ID: 36805688
[TBL] [Abstract][Full Text] [Related]
33. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
34. Targeting post-translational histone modifying enzymes in glioblastoma.
Kunadis E; Lakiotaki E; Korkolopoulou P; Piperi C
Pharmacol Ther; 2021 Apr; 220():107721. PubMed ID: 33144118
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems.
Nguyen TTT; Zhang Y; Shang E; Shu C; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Cells; 2020 Jul; 9(7):. PubMed ID: 32664214
[TBL] [Abstract][Full Text] [Related]
38. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment.
Stettner M; Kaulfuss S; Burfeind P; Schweyer S; Strauss A; Ringert RH; Thelen P
Mol Cancer Ther; 2007 Oct; 6(10):2626-33. PubMed ID: 17913855
[TBL] [Abstract][Full Text] [Related]
39. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]